Join to View Full Profile
825 Eastlake Ave ESeattle, WA 98109
Phone+1 206-520-5000
Dr. Banerjee is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Rahul Banerjee, MD, FACP, (Twitter/X: @RahulBanerjeeMD) is an Assistant Professor at the Fred Hutchinson Cancer Center and at the University of Washington in Seattle, WA. His clinical interests are in multiple myeloma and CAR-T therapy. He is a member of the International Myeloma Working Group and has published over 90 peer-reviewed publications with an emphasis on improving the experiences of patients as they undergo treatment for multiple myeloma.
Education & Training
University of California San FranciscoAdvanced Fellowship, BMT/CAR-T Therapy, 2021 - 2022
University of California (San Francisco)Fellowship, Hematology and Medical Oncology, 2018 - 2021
University of Pennsylvania Health SystemChief Residency, Internal Medicine, 2017 - 2018- University of Pennsylvania Health SystemResidency, Internal Medicine, 2014 - 2017
- University of Pennsylvania Health SystemInternship, Internal Medicine, 2014 - 2015
The Warren Alpert Medical School of Brown UniversityClass of 2014, MD, AOA Inductee
Certifications & Licensure
WA State Medical License 2022 - 2027
AK State Medical License 2025 - 2026
CA State Medical License 2018 - 2026
ID State Medical License 2024 - 2026
MT State Medical License 2024 - 2026
PA State Medical License 2014 - 2018
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- Winner, Department of Medicine ‘Shelter-in-Poetry’ Competition University of California San Francisco, 2020
- Penn Pearls Award Recipient Perelman School of Medicine, University of Pennsylvania, 2017
- Samaha Award for resident scholarship Penn Medicine, 2017
- Join now to see all
Clinical Trials
- Digital Life Coaching for Myeloma Patients Undergoing Transplantation Start of enrollment: 2020 May 20
- Randomized Study of Digital Life Coaching in Myeloma Patients Undergoing Transplantation Start of enrollment: 2020 Dec 29
- Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma with Isatuximab Start of enrollment: 2022 Jun 17
- Join now to see all
Publications & Presentations
PubMed
- Teclistamab for Patients with Heavily Pretreated Relapsed/Refractory Multiple Myeloma and Renal Impairment.Danai Dima, Aimaz Afrough, Utkarsh Goel, Ariel Grajales-Cruz, Jack Khouri
Blood Advances. 2025-04-08 - Real-world treatment patterns for teclistamab and talquetamab in multiple myeloma (MM): experience from 609 patients.Farheen Chunara, Chris Lugo, Kristen Osinski, Mansi R Shah, Nishi Shah
Blood Cancer Journal. 2025-04-08 - Urine-free response criteria predict progression-free survival in multiple myeloma: a post hoc analysis of BMT CTN 0702.Rahul Banerjee, Amber R Fritz, Othman S Akhtar, Ciara L Freeman, Andrew J Cowan
Leukemia. 2025-04-01
Journal Articles
- IlliteracyBanerjee R, The Pharos of Alpha Omega Alpha Honor Medical Society, 2/21/2017
Books/Book Chapters
Press Mentions
Multiple myeloma is treatable, not curable. Is that set to change?April 4th, 2025
Multiple Myeloma Is Treatable, Not Curable. Is That Set to Change?April 3rd, 2025- The Rapid Evolution of Multiple Myeloma Treatment in Recent YearsFebruary 26th, 2025
- Join now to see all
Grant Support
- Young Investigator AwardASCO Conquer Cancer Foundation2020–2022
Professional Memberships
- Member
- Member
- Member
- Member
- American Society for Transplantation and Cellular TherapyMember
- Member
Other Languages
- Hindi, Bengali
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
